Skip to main content

A randomized prospective study: assessment of transient ureteral stenting by mono-J insertion after primary URS and stone extraction (FaST 3)


To compare the outcome of a short-term insertion of a mono-J catheter for 6 h following ureteroscopic stone removal to a conventional double-J catheter. This single-center academic study (Fast Track Stent study 3) evaluated stenting in 108 patients with urinary calculi after ureterorenoscopy. Patients were prospectively randomized into two study arms before primary ureterorenoscopy: (1) mono-J insertion for 6 h after ureterorenoscopy and (2) double-J insertion for 3–5 days after ureterorenoscopy. Study endpoints were stent-related symptoms assessed by an ureteral stent symptom questionnaire (USSQ) and reintervention rates. Stone sizes and location, age, operation duration, BMI, and gender were recorded. Of 67 patients undergoing ureterorenoscopy, 36 patients were analyzed in the double-J arm and 31 patients in the mono-J arm. Mean operation time was 27.5 ± 1.3 min versus 24.0 ± 1.3 min, and stone size was 5.2 mm versus 4.5 mm for mono-J versus double-J, respectively (p = 0.06 and p = 0.15). FaST 3 was terminated early due to a high reintervention rate of 35.5% for the mono-J group and 16.7% for the double-J group (p = 0.27). One day after ureterorenoscopy, USSQ scores were similar between the study arms (Urinary Index: p = 0.09; Pain Index: p = 0.67). However, after 3–5 weeks, the Pain Index was significantly lower in those patients who had a double-J inserted after ureterorenoscopy (p = 0.04). Short-term insertion of mono-J post-ureterorenoscopy results in similar micturition symptoms and pain one day after ureterorenoscopy compared to double-J insertion. The reintervention rate was non-significant between the treatment groups most likely due to the early termination of the study (p = 0.27). Ethics approval/Trail Registration: No. 18-6435, 2018


The necessity for stenting after ureterorenoscopy (URS) has been widely discussed, and practice differs internationally [1]. Potential benefits and adverse effects of stent insertion have to be balanced. Stents are often inserted prophylactically, as ureteral manipulation can cause swelling and obstruction. Meta-analyses found no difference in stone-free rates (SFR) [2,3,4]. However, patients who were stented after URS were more likely to complain of irritative micturition symptoms compared to those who did not receive a stent.

European and American guidelines state that urologists can omit stenting after uncomplicated URS and complete stone removal [5, 6].

The Fast Track Stent Studies (FaST 1–3) are successive, prospective randomized trials with similar designs to evaluate drainage after URS [7,8,9,10].

FaST 1 compared a double-J (DJ) insertion for 3–5 days to a mono-J (MJ) insertion for 6 h after secondary URS (Fig. 1). Patients with a MJ reported fewer irritative micturition symptoms and pain and reported a better performance in everyday life, while the reintervention rate was higher compared to patients who had a DJ inserted [7]. FaST 2 compared a MJ placement with an indwelling time of 6 h to a tubeless procedure after secondary URS (Fig. 1). Patients from both study arms experienced a significantly improved QoL after URS. However, reintervention rates were significantly lower in patients with a MJ (1.6 %versus 13.3%) [8].

Fig. 1

Overview FaST (1, 2 and 3) trials. Patients in all trials were enrolled and randomized before URS. Each study comprised of two arms comparing drainage after stone extraction. In the FaST 1 and 2 trials, patients were pre-stented. Patients in the FaST 1 and 2 studies completed the USSQ one day before and 3–5 weeks after URS. FaST 3 study collected USSQ results one day and 3–5 weeks after URS

Furthermore, the necessity of stenting before URS is a matter of debate. The American guidelines provide a strong recommendation against routine stent placement [5]. Moreover, The European and German Urological Associations state that routine stenting before URS is not necessary. However, they note that pre-stenting improves outcomes and decreases complications (Level 1b) [6, 11].

Current studies show that German practices often deviate from recommendations in the guidelines [12]. For example, data from the German BUSTER study shows that pre-stenting is performed in 70% of patients before stone extraction in Germany [13].

The present work aims to analyze the safety of MJ insertion after primary URS and whether stent-associated symptoms can be reduced by inserting a MJ instead of a DJ after URS.


The FaST 3 recruited patients from 07/2018 to 09/2020. Ethics approval was obtained through the Ruhr University of Bochum (No. 18-6435).

In this academic, single-center trial, patients were assigned via block randomization with an allocation ratio of 1:1 to a DJ placement for 3–5 days or a short-term MJ insertion for 6 h. Patients at least 18 years of age who had a URS planned for ureteral or renal stones smaller than 15 mm were eligible for this study. Those with a single kidney or concurrent urinary tract infections were not eligible. Additionally, if patients were ineligible for primary URS due to strictures, the SFR was below 80% after primary URS, operation time exceeded one hour, or complications occurred (American Association for the Surgery of Trauma-Organ Injury Scale (AAST) Grade 2), patients were secondarily excluded. Termination criterion was a reintervention rate of > 30%. Single-dose parenteral antibiotic therapy was administered before surgery. Six surgeons, not blinded to randomization, performed URS using a 6.4 Fr/4.2 Fr channel semirigid instrument by Olympus® and a 9.9 Fr flexible URS instrument by Olympus®. For flexible URS, access sheaths (12 Fr, Coloplast©) were used. A holmium laser (LISALaser®) was used for lithotripsy and set to 80 Hz and 0.3 Joule to dust stones. After stone removal, SFR was checked fluoroscopically, and stents were inserted. Depending on the study arm, either a DJ by Coloplast® (6 Fr, 26 cm) or a MJ by Coloplast® (VORTEK®, 6 Fr) was placed. Nurses pulled out the MJs on the ward after 6 h. After URS, patients received diclofenac (50 mg orally, twice daily) and tamsulosin off label (0.4 mg orally, once daily) over three days.

Primary endpoints were urinary symptoms on day 1 and 3–5 weeks after URS assessed using the USSQ. Secondary endpoints were reintervention rates and pain, QoL, work performance, sexual concerns and additional problems, also assessed by the USSQ [10]. The USSQ is a validated questionnaire with good internal consistency and test–retest reliability. It comprises 6 sections with 38 questions regarding stent-associated symptoms. A sample size of 53 patients in each group is required to demonstrate a difference of 15% in the Urinary Symptoms Index between populations with a statistical power of 80% [10]. Intention-to-treat analysis was applied in the present study. Crossovers were transferred from the original to the new treatment group. Missing data were deleted pairwise. We used GraphPad Prism 5 for statistical analysis. Patients' characteristics were examined using Student's t test and Fisher's exact test. USSQ results and reintervention rates were compared using a Mann–Whitney U test, Student's t test and Fisher's exact test. The level of significance was defined as p < 0.05.


One hundred eight patients were assessed for eligibility. Seven patients had to be excluded because they did not meet the inclusion criteria (n = 7). None of the patients declined to participate (n = 0). One hundred one patients met the inclusion criteria and gave informed consent to participate (Fig. 2). Patients were randomly allocated to two interventions after URS: DJ drainage for 3–5 days (n = 47) or MJ drainage for 6 h (n = 54). Two patients who were initially randomized into the MJ arm were crossed over into the DJ group by the surgeon. Thirty-four patients were secondarily excluded. Thirty-six patients were analyzed in the DJ arm and thirty-one in the MJ arm. In fifteen patients, USSQ results were incomplete because they were lost to follow-up. Patient characteristics are shown in Table 1. The MJ and DJ groups were not statistically different in terms of stone size, stone density, number of semirigid and flexible URS procedures, age, operation duration, or body mass index (BMI) (Table 1).

Fig. 2

FaST 3 study flowchart

Table 1 Patient characteristic


Due to high reintervention rates in the MJ group, early termination of the study was necessary. Reintervention rates did not differ significantly according to the randomization group (Table 2). Reasons for reintervention were symptomatic hydronephrosis (visual analogue scale > 7) or fever (> 38.5 °C) following URS. Reinterventions were required in 35.5% (11 out of 31) of patients in the MJ group and 16.7% (6 out of 36) in the DJ population (p = 0.27). In case of reintervention, a DJ stent by Coloplast© (7 Fr, 26 cm) was placed. Follow-up procedures were carried out within 48 h of stone removal.

Table 2 USSQ results one day after and 3-5 weeks after stone removal and reintervention rates

Subgroup analysis of mono-J patients (Table 3) did not identify pre- or intraoperative parameters that increased postoperative reintervention risk.

Table 3 Comparison of patients who required versus patients who did not require reintervention after URS and short-term MJ insertion

USSQ: urinary concerns

On the day after stone removal, the Urinary Index did not differ between the MJ and DJ groups (p = 0.04; Fig. 3, Table 2). All patients reported that they had “a little bit" to "moderate" of micturition complaints after intervention (Q U10: p = 0.76). Patients from both study arms responded that they would have "mixed feelings" to question U11: “If you were to spend the rest of your life with the urinary symptoms, if any, associated with the kidney problem just the way they are, how would you feel about it?" (Q U11: p = 0.21). After 3–5 weeks, patients from both study arms answered the same question and stated they would feel "pleased" to "delighted" (Q U11: p = 0.43). Moreover, micturition complaints decreased in both study arms without a significant difference between the groups.

Fig. 3

FaST 3 Study USSQ indices (Urinary, Pain, General Health, Work and Sexual Index). Urinary Index: (1) DJ: n = 24, MJ: n = 28, p = 0.14; (2) DJ: n 27, MJ: n = 25, p = 0.43. Pain Index: (1) DJ: n = 28, MJ: n = 29, p = 0.67; (2) DJ: n 27, MJ: n = 26, p = 0.04. General Health Index: DJ: n = 27, MJ: n = 25, p = 0.13. Work Index: DJ: n = 12, MJ: n = 21, p = 0.90. Sexual Index: DJ: n = 14, MJ: n = 17, p = 0.94. Boxplot: whiskers: min and max, mean shown as  + , median shown as a horizontal line

USSQ: pain concerns

Pain was reported by 62.1% of DJ versus 67.9% of MJ patients one day after URS (p = 0.78). Three to five weeks after URS, the incidence of pain was 61.5% for patients of the MJ group and reduced to 44.4% for those in the DJ group (p = 0.27).

On day one after URS and stone removal, the Pain Index did not differ significantly between the study arms (p = 0.67; Table 2, Fig. 3). After 3–5 weeks, patients from the DJ group showed a lower Pain Index (p = 0.04).

USSQ: general health concerns

The drainage applied after URS had no impact on the General Health Index 3– 5 weeks after URS (p = 0.13; Table 2 and Fig. 3).

Question GQ asked about patients' feelings if they were advised to have a stent inserted in future. On the day after URS, all patients stated they would have "mixed feelings" to feel "mostly satisfied" (Q GQ: p = 0.22; Table 2). During the follow-up questioning, MJ and DJ patients reported they were "mostly satisfied" (Q GQ: p = 0.06) (Table 2).

USSQ: return to work

Functional limitations were not an issue in either of the treatment arms. Immobilization was rare (MJ:1.1 versus DJ: 1.2 days; p = 0.51). Patients experienced a limitation in daily activities for MJ: 2.8 versus DJ: 2.6 days (p = 0.74). Regardless of drainage, the Work Index was similar (p = 0.90; Table 2 and Fig. 3).

USSQ: additional concerns

After URS, most patients did not report symptoms associated with urinary tract infection. This finding was related to neither MJ nor DJ insertion (Q A1: p = 0.98). The type of urinary drainage did not result in additional visits to a doctor (Q A3: p = 0.37) or repeat hospital admissions following therapy (Q A4: p = 0.82).

Ineligibility for primary URS

10.3% of patients randomized in the FaST 3 were not eligible for primary URS due to ureteral strictures and thus were secondarily excluded. The assessment of eligibility for URS was at the urologist's discretion.


To our knowledge, the FaST 3 is the first prospective randomized study comparing a MJ insertion to a DJ insertion after primary URS. This study is preceded by the FaST 1 and 2, which evaluated short-term MJ placement, DJ placement, and omission of stenting after secondary URS [7, 8]. We demonstrated that patients benefit from significantly improved urinary symptoms, pain, general health and workability if a MJ is transiently placed or no stent is inserted. However, reintervention rates differed significantly, with no reintervention in the DJ arm, 5.0% in the MJ arm and 13.3% if stenting is omitted.

Postoperative stenting

American, European and German guidelines agree that routine stenting after URS is not necessary [5, 6, 11, 12]. A Cochrane analysis including 23 trials and 2,656 patients addressing the effect of postoperative ureteral stent placement after uncomplicated URS showed that stenting slightly reduces the risk of unplanned return visits and has little to no impact on secondary interventions and postoperative pain. However, they outlined that the certainty of the evidence is low to very low [14].

The European guidelines advise that "a ureteral catheter with a shorter indwelling time (one day) may also be used", referring to an editorial comment by Moon et al. [6, 15].

FaST 3 compared a transient MJ to a DJ placement after primary URS. QoL in terms of micturition symptoms and pain was comparable one day after URS across both randomized groups. 3–5 weeks after URS, the Pain Index was significantly higher in the MJ group, while micturition symptoms did not differ significantly. No difference was found regarding general health, sexual complaints, or the ability to work. The reintervention rate was higher when a MJ was transiently inserted (32.2% versus 19.4; p = 0.27), though without significance. A prospective observational, international multicentre study by the Endourologic Society (CROES) showed that stenting after removal of both ureteral and renal stones reduces the risk of complications (p < 0.001) [1]. In a retrospective study, Merlo et al. compared a DJ placement (2–4 weeks) to a MJ placement (up to 24 h) to an omission of stenting after URS. One month after URS, patients with transient MJ placement reported LUTS incidence, hematuria, pain, fever and required hospital care significantly less often than patients who had received a DJ.

Literature suggests that contrary to the guidelines, DJ stent use after URS is very common. An analysis of postoperative DJ stenting by the CROS study group showed that the USA, China, Canada and Japan placed DJ stents postoperatively in more than 90% of patients [1]. A survey among German urological departments showed that after primary URS, 79.6% of urologists inserted a DJ, 7.3% inserted a MJ, and 3.6% omitted a stent. After secondary URS, urologists inserted a DJ in 62.2% of cases, a MJ in 10.5% and did not insert a stent in 14.0% [16].

We conclude that in our study cohort, routine placement of a MJ for 6 h after URS is not safe considering the high reintervention rate.

Primary URS

Guidelines claim that stenting before uncomplicated URS is not necessary [5, 11]. "However, pre-stenting facilitates ureteroscopic management of stones, improves the SFR, and reduces intra-operative complications" [6]. The CROES URS Global Study (n = 8189 patients with ureteral calculi) showed that in 12.7% of cases before semirigid URS and 37.8% before flexible URS, a DJ was inserted preoperatively [17]. The share of pre-stented patients was exceptionally high in Germany. In the FaST 3 protocol, 10.3% of all patients required pre-stenting. Those patients were excluded as they were ineligible for primary URS. Comparing the reintervention rates of the FaST 3 to those of FaST 1 and 2 allow for a comparison of reintervention rates between primary and secondary URS in the same clinical setting [7, 8]. If a DJ was inserted, no reinterventions were necessary for pre-stented patients, while the reintervention rate was 16.7% after primary URS (p = 0.002). If a MJ was inserted, reinterventions were necessary for 5.0% of pre-stented patients, while the reintervention rate was 35.5% after primary URS (p < 0.0001). Comparing the existing literature is difficult: while most studies report about complications versus the need for reintervention, a database study on postoperative stenting, including a heterogeneous population of 11,885 patients, reported that 16.0% needed retreatment, including readmission [18]. The operative reintervention rate in the FaST 3 collective is high; an explanation might be the study's prospective character. Urologists were required to stick to the study protocol; however, the eligibility for a primary URS was at the surgeons' discretion.

Remarkably, treatment modalities (high rate of pre-stenting) deviate in a highly developed country with a well-equipped health system like Germany, and this could be due to financial incentives and a missing endourological department system [16].

Our study has limitations. First, surgeons might have been biased as they were aware of the treatment allocation. A second limitation is that patients were aware of this allocation, which possibly affected USSQ results. FaST 3 was preliminarily terminated due to the high reintervention rate in both groups, thus did not achieve the required sample size.

Given the high rate for postoperative reintervention, short-term mono-J drainage after primary URS is only reasonable for a selected patient collective and depends on surgeons' assessment.



American Association for the Surgery of Trauma (ureter)


Body mass index


Clinical Research Office of Endourological Society


Double-J stent


Mono-J stent


Fast track stent studies


Quality of life


Stone free rate




Ureteral stent symptom questionnaire


  1. 1.

    Muslumanoglu AY, Fuglsig S, Frattini A et al (2017) Risks and benefits of postoperative double-J stent placement after ureteroscopy: results from the clinical research office of endourological society ureteroscopy global study. J Endourol 31:446–451.

    Article  PubMed  Google Scholar 

  2. 2.

    Song T, Liao B, Zheng S et al (2012) Meta-analysis of postoperatively stenting or not in patients underwent ureteroscopic lithotripsy. Urol Res 40:67–77.

    Article  PubMed  Google Scholar 

  3. 3.

    Haleblian G, Kijvikai K, La Rosette J, de, et al (2008) Ureteral stenting and urinary stone management: a systematic review. J Urol 179:424–430.

    Article  PubMed  Google Scholar 

  4. 4.

    Nabi G, Cook J, N’Dow J et al (2007) Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ 334:572.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Assimos D, Krambeck A, Miller NL et al (2016) Surgical management of stones: American Urological Association/Endourological Society Guideline. J Urol 196:1161

    Article  Google Scholar 

  6. 6.

    Türk C, Neisius A, Petrik A (2021) Guidelines on urolithiasis

  7. 7.

    Bach P, Reicherz A, Teichman J et al (2018) Short-term external ureter stenting shows significant benefit in comparison to routine double-J stent placement after ureterorenoscopic stone extraction: a prospective randomized trial—the fast track stent study (FaST). Int J Urol 25:717–722.

    Article  PubMed  Google Scholar 

  8. 8.

    Reicherz A, Maas V, Wenzel P et al (2020) Transient stent placement versus tubeless procedure after ureteroscopy retrograde surgery stone extraction (Fast Track Stent study 2): a randomized prospective evaluation. Int J Urol 27:749–754.

    Article  PubMed  Google Scholar 

  9. 9.

    Reicherz A, Maas V, Reike M et al (2021) Striking a balance: outcomes of short-term Mono-J placement following ureterorenoscopy. Urolithiasis.

    Article  PubMed  Google Scholar 

  10. 10.

    Joshi HB, Newns N, Stainthorpe A et al (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Arbeitskreis Harnsteine der Akademie der Deutschen Urologen (2018) S2k-Leitlinie zur Diagnostik, Therapie und Metaphylaxe der Urolithiasis

  12. 12.

    Lebentrau S, May M, Ziegler H et al (2018) Die Empfehlungen der S2k-Leitlinie zur Diagnostik, Therapie und Metaphylaxe der Urolithiasis bilden einen sicheren Handlungskorridor für die ureterorenoskopische Steintherapie—Ergebnisse der BUSTER-Studie (the recommendations of the S2k guideline for the diagnosis, therapy and metaphylaxis of urolithiasis provide a safe course of action for ureterorenoscopic stone treatment—results of the BUSTER study). Aktuelle Urol 49:164–170.

    Article  PubMed  Google Scholar 

  13. 13.

    Werthemann P, Weikert S, Enzmann T et al (2020) A stent for every stone? Prestenting habits and outcomes from a German multicenter prospective study on the benchmarks of ureteroroscopic stone treatment (BUSTER). Urol Int 104:431–436.

    Article  PubMed  Google Scholar 

  14. 14.

    Ordonez M, Hwang EC, Borofsky M et al (2019) Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi. Cochrane Database Syst Rev.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Moon TD (2002) Ureteral stenting—an obsolete procedure? J Urol 167:1984

    Article  Google Scholar 

  16. 16.

    Reicherz A, Sahin R, Häuser L et al (2021) An empirical study on the operative treatment of symptomatic urolithiasis in Germany. Urol Int 105:240–246.

    Article  PubMed  Google Scholar 

  17. 17.

    Assimos D, Crisci A, Culkin D et al (2016) Preoperative JJ stent placement in ureteric and renal stone treatment: results from the Clinical Research Office of Endourological Society (CROES) ureteroscopy (URS) Global Study. BJU Int 117:648–654.

    Article  PubMed  Google Scholar 

  18. 18.

    Somani BK, Giusti G, Sun Y et al (2017) Complications associated with ureterorenoscopy (URS) related to treatment of urolithiasis: the Clinical Research Office of Endourological Society URS Global study. World J Urol 35:675–681.

    CAS  Article  PubMed  Google Scholar 

Download references


Open Access funding enabled and organized by Projekt DEAL. None.

Author information




All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by AR, HW, LH, PW, JN and PB. The first draft of the manuscript was written by AR and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Alina Reicherz.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Medical University of Ruhr University Bochum, Germany (No. 18–6435).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 101 KB)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reicherz, A., Westhues, H., Häuser, L. et al. A randomized prospective study: assessment of transient ureteral stenting by mono-J insertion after primary URS and stone extraction (FaST 3). Urolithiasis (2021).

Download citation


  • Ureteroscopy
  • Urolithiasis
  • Flexible ureteroscopy
  • Double-J
  • Transient ureteral stenting using a mono-J ureteral catheter